Stay updated on Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.

Latest updates to the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedRevision: v3.3.2 updated from v3.3.1; no substantive study information is affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check24 days agoChange DetectedPubMed auto-fill clarification and a new Revision: v3.3.1 have been added to the Publications section. The previous PubMed auto-fill description and Revision: v3.2.0 text were removed.SummaryDifference0.0%

- Check31 days agoChange DetectedAdded a new trial site in Tainan, Taiwan (704) on 2025-11-13, with related updates on 2025-11-06 and 2025-11.SummaryDifference0.2%

- Check38 days agoChange DetectedAdded a new NEJM publication entry for MARIPOSA: Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC (N Engl J Med, Oct 30, 2025; DOI: 10.1056/NEJMoa2503001; Epub Sep 7, 2025). Removed the previous 'Online ahead of print' listing for the same article (Sept 7, 2025).SummaryDifference0.0%

- Check46 days agoChange DetectedCore study details (interventions, eligibility criteria, endpoints) appear unchanged between screenshots, with only non-critical metadata differences such as update timestamps visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check74 days agoChange DetectedAdded a government funding/status notice and updated version to v3.2.0; removed the old v3.0.2 reference.SummaryDifference2%

Stay in the know with updates to Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.